Sarepta Shares Surge as FDA Approves Resumption of Elevidys Shipments
TL;DR
Sarepta Therapeutics' shares rebounded after the FDA approved the resumption of shipments for its gene therapy Elevidys in the US for ambulatory patients with Duchenne muscular dystrophy, easing concerns about liquidity and market withdrawal, though shipments for non-ambulatory patients remain halted following recent deaths and regulatory scrutiny.
Topics:business#business#duchenne-muscular-dystrophy#elevidys#gene-therapy#market-resumption#sarepta
- Sarepta shares rebound after shipments of gene therapy Elevidys resume in US Yahoo Finance
- Sarepta can begin shipping Elevidys therapy after FDA reverses pause; stock soars. Yahoo Finance
- FDA Informs Sarepta That It Recommends That Sarepta Remove Its Pause and Resume Shipments of ELEVIDYS for Ambulatory Individuals With Duchenne Muscular Dystrophy Sarepta Therapeutics
- Sarepta Stock Soars After FDA Says It Can Resume Drug Shipments Investor's Business Daily
- Sarepta resumes shipping of gene therapy Elevidys to patients who can walk Reuters
Want the full story? Read the original reporting
Read on Yahoo Finance